Skip to content

Zymeworks ZYME Payments to Acquire Marketable Securities

Payments to Acquire Marketable Securities at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$166.31M+0.8%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's payments to acquire marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's payments to acquire marketable securities?
Zymeworks (ZYME) reported payments to acquire marketable securities of $0 in Q1 2026.
How has Zymeworks's payments to acquire marketable securities changed year-over-year?
Zymeworks's payments to acquire marketable securities decreased by 100.0% year-over-year, from $34.03M to $0.
What does payments to acquire marketable securities mean?
Cash outflows directed toward the purchase of short-term or long-term investment-grade financial instruments. This reflects the company's strategy for managing excess cash and liquidity by earning interest on idle capital.